The London Stock Exchange uses cookies to improve its website. The cookies for analytical purposes have already been set. For more details and how to manage cookies, please see our privacy and cookies policy.


AZN ASTRAZENECA PLC ORD SHS $0.25

ASTRAZENECA  Currency  GBX  Premium Equity Commercial Companies



 Page 4 of 5

Previous | 1 | 2 | 3 | 4 | 5 | Next

Time/Date Code Headline Source Impact
15:00 01-Aug-2013 AZN Director/PDMR Shareholding RNS -0.89% Down
07:00 01-Aug-2013 AZN Half Yearly Pipeline Update RNS -0.89% Down
07:00 01-Aug-2013 AZN Half Yearly Report RNS -0.89% Down
09:00 31-Jul-2013 AZN Notice of Results RNS +0.11% Up
07:00 31-Jul-2013 AZN Collaborates with FibroGen on anaemia treatment RNS +0.11% Up
07:00 26-Jul-2013 AZN FDA receipt of dapagliflozin resubmission RNS +1.11% Up
07:00 19-Jul-2013 AZN AstraZeneca completes acquisition of Omthera RNS -0.08% Down
07:00 15-Jul-2013 AZN Simon Lowth, CFO, to leave AstraZeneca RNS +0.53% Up
16:30 11-Jul-2013 AZN Holding(s) in Company RNS +0.82% Up
15:00 01-Jul-2013 AZN Total Voting Rights RNS +2.58% Up
17:35 28-Jun-2013 AZN Publication of Prospectus RNS +2.65% Up
07:00 28-Jun-2013 AZN Completes Acquisition of Pearl Therapeutics RNS +2.65% Up
07:00 19-Jun-2013 AZN Announces top-line results for SAVOR study RNS -4.71% Down
15:00 12-Jun-2013 AZN Director/PDMR Shareholding RNS -1.31% Down
15:00 12-Jun-2013 AZN Director/PDMR Shareholding RNS -1.31% Down
15:00 12-Jun-2013 AZN Director/PDMR Shareholding RNS -1.31% Down
07:00 10-Jun-2013 AZN To Acquire Pearl Therapeutics RNS -1.56% Down
07:00 04-Jun-2013 AZN Top-line results from Phase III Oskira trials RNS -3.06% Down
13:00 03-Jun-2013 AZN Blocklisting Interim Review RNS -3.68% Down
12:00 03-Jun-2013 AZN Total Voting Rights RNS -3.68% Down

 Page 4 of 5

Previous | 1 | 2 | 3 | 4 | 5 | Next

Price changes are calculated on the basis of the following formula: [avg(x) - avg(y)] / avg(y) where:
x = instrument's 7 closing prices after the news has been released
y = instrument's latest 7 closing prices before the news was released, including the day of the release of the news

Please note that the news releases are only one of the multiple factors that could have had an impact on the change in the security’s
price over the time period analysed by the News Analysis tool.


ASTRAZENECA share - news analysis

The Exchange accepts no responsibility for the content of the website you are now accessing or for any reliance placed by you or any person on the information contained on it.

By allowing this link the Exchange does not intend in any country, directly or indirectly, to solicit business or offer any securities to any person.

You will be redirected in five seconds.

You are accessing the London Stock Exchange Annual Report Service powered by PrecisionIR.

The Exchange accepts no responsibility for the content of the reports you are now accessing or for any reliance placed by you or any person on the information contained therein.

By allowing this link the Exchange does not intend in any country, directly or indirectly, to solicit business or offer any securities to any person.

You will be redirected in five seconds